How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Research Animal Models Market
- By Animal Species: Rodents (Mice, Rats), Non-Human Primates, Canines, Felines, Zebrafish, Rabbits
- By Model Type: Genetically Engineered Models, Induced Models, Spontaneous Models, Xenograft Models, Transgenic Models
- By Application: Oncology Research, Neuroscience Research, Cardiovascular Research, Immunology Research, Infectious Disease Research, Metabolic Disease Research
- By End User: Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), Government & Regulatory Agencies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Rodents (Mice, Rats) leads By Animal Species at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Research Animal Models Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Animal Species 6
Model Type 5
Application 6
End User 4
Companies profiled
Charles River Laboratories International Inc.
Envigo (a part of Inotiv)
Taconic Biosciences Inc.
Covance Inc. (LabCorp)
Janvier Labs
Oriental BioService Inc.
SLC (SLC Laboratory Co. Ltd.)
Biocytogen Co. Ltd.
Cyagen Biosciences Inc.
GemPharmatech Co. Ltd.
Envigo RMS (now part of Inotiv)
Harlan Laboratories (acquired by Envigo)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Covance Inc. (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Janvier Labs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Oriental BioService Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SLC (SLC Laboratory Co. Ltd.)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Biocytogen Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cyagen Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →GemPharmatech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Envigo RMS (now part of Inotiv)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Harlan Laboratories (acquired by Envigo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Jackson Laboratory
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Envigo CRS
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Envigo Research Models and Services
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,542M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Rodents (Mice, Rats)48.5
- Non-Human Primates8.5
- Canines12.2
- Felines12.6
- Zebrafish5.4
- Rabbits12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,131M → $2,529M · 10.6%
Europe$788.1M → $1,880M · 11.5%
Asia Pacific$719.6M → $1,513M · 9.7%
Latin America$445.5M → $958.7M · 10.1%
Middle East and Africa$342.7M → $831.4M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.322026
10.342027
10.332028
10.362029
10.362030
10.382031
10.392032
10.402033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.17.8
- Envigo (a part of Inotiv)21.6
- Taconic Biosciences Inc.5.8
- Covance Inc. (LabCorp)9.8
- Janvier Labs8.3
- Oriental BioService Inc.8.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Animal Species20.2%
Model Type22.9%
Application34.4%
End User22.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe24.4
- Asia Pacific19.6
- Latin America12.4
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 90 | 94 | 96 | 93 | 98 | 79 | 92 |
| Envigo (a part of Inotiv) | 73 | 75 | 69 | 93 | 80 | 81 | 79 |
| Taconic Biosciences Inc. | 71 | 68 | 74 | 78 | 85 | 64 | 73 |
| Covance Inc. (LabCorp) | 67 | 66 | 57 | 68 | 69 | 75 | 67 |
| Janvier Labs | 69 | 59 | 63 | 65 | 77 | 62 | 66 |
| Oriental BioService Inc. | 64 | 64 | 46 | 63 | 62 | 69 | 61 |
| SLC (SLC Laboratory Co. Ltd.) | 66 | 45 | 66 | 65 | 42 | 54 | 56 |
| Biocytogen Co. Ltd. | 54 | 54 | 36 | 41 | 58 | 38 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Envigo (a part of Inotiv)
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Envigo (a part of Inotiv) | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Taconic Biosciences Inc. | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Covance Inc. (LabCorp) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Janvier Labs | − | ◐ | ◐ | ✓ | ✓ | ◐ |
| Oriental BioService Inc. | ◐ | ✓ | − | ◐ | − | ◐ |
| SLC (SLC Laboratory Co. Ltd.) | − | ◐ | ✓ | − | − | ◐ |
| Biocytogen Co. Ltd. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.92
2Envigo (a part of Inotiv)79
3Taconic Biosciences Inc.73
4Covance Inc. (LabCorp)67
5Janvier Labs66
6Oriental BioService Inc.61
7SLC (SLC Laboratory Co. Ltd.)56
8Biocytogen Co. Ltd.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Envigo (a part of Inotiv)
Challenger2
Strong scale, closing on the leaders.
Taconic Biosciences Inc.Covance Inc. (LabCorp)
Contender2
Focused players with pockets of strength.
Janvier LabsOriental BioService Inc.
Niche2
Specialists in a single segment or region.
SLC (SLC Laboratory Co. Ltd.)Biocytogen Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Animal Species in North America, then scale across Research Animal Models Market — a $590M beachhead inside a $8.97B market.
Beachhead (SOM)$590Mobtainable near-term
Serviceable (SAM)$3.25Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Rodents (Mice, Rats)
Best fit — highest urgency & budget in Animal Species.
Economic buyer77 fit
Non-Human Primates
Strong fit — clear ROI and a fast path to value.
End user66 fit
Canines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Animal Species in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Model Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Animal Species leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Research Animal Models Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation12%
Closed-won7%
$8.4KCAC
$35KLTV
4.2:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Research Animal Models Market is a durable-growth opportunity — $1.82B by 2033, compounding at 8.2%.
TAM · 2025$968Mtoday
TAM · 2033$1.82Bforecast
CAGR8.2%2027–2033
Cumulative$12.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.82BTotal addressable market
SAM$677MServiceable available market
SOM$128MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.2% CAGR
Demand compounds through 2033, outpacing GDP across Animal Species.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Animal Species moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.82BLarge & growingTAM by 2033 at 8.2% CAGR
$677MServiceable nowreachable with today’s model
$128MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.42BBear5.4% CAGR
$1.82BBase8.2% CAGR
$2.34BBull10.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Model Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Research Animal Models Market — a $12.6B market by 2033. Plan: grow share from 8.8% to 15.2%.
Market size · 2033$12.6Btotal addressable
Market CAGR11.4%2027–2033
Target share15.2%from 8.8% today
Revenue ambition$1.91Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 15.2% | On track |
| Revenue | $1.04B | $1.91B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 34.2% | 40.6% | Behind |
| Customer retention | 86.0% | 96.4% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Animal Species
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Model Type capability
A defensible second engine — invest in Model Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Animal Species share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Model Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $218M capacity & capability investment
- Greenlight bolt-on M&A in Model Type
- Authorise North America expansion plan
- Fund R&D program for Animal Species leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Research Animal Models Market conversation — a $4.26B market you can size, segment and defend in minutes.
Market size · 2033$4.26Btotal opportunity
Growth10.4%CAGR to 2033
Addressable buyers1,499+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Animal Species
Goal Grow share in Animal Species
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$70K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Envigo (a part of Inotiv)Taconic Biosciences Inc.Covance Inc. (LabCorp)Janvier LabsOriental BioService Inc.SLC (SLC Laboratory Co. Ltd.)Biocytogen Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Research Animal Models Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Research Animal Models Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Research and Development Service Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportRescue Trauma Shear Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportRescue Pack Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportRescue Inhaler Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportRescue and Medical Training Services Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportRescue and Maintenance Inhalers Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportRescue and First Aid Equipment Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportRescue Airway Devices Market
Market size, share, segmentation and regional forecast.
$375M market · 2025 base year
View reportRepurposed Drugs Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportReproductive System Anatomical Model Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportReproductive Medicine Microscope Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportReproductive Hormone Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.